Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Biotime's Ownership of Outstanding Shares of Its Subsidiaries

BioTime’s condensed consolidated interim financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of June 30, 2019.

Subsidiary	Field of Business	BioTime Ownership		Country
Asterias BioTherapeutics, Inc.	Cell therapy clinical development programs in spinal cord injury and oncology		100%	USA
Cell Cure Neurosciences Ltd. (“Cell Cure”)	Products to treat age-related macular degeneration		99% (1)	Israel
ES Cell International Pte. Ltd. (“ESI”)	Stem cell products for research, including clinical grade cell lines produced under cGMP		100%	Singapore
OrthoCyte Corporation (“OrthoCyte”)	Developing bone grafting products for orthopedic diseases and injuries		99.8%	USA

⁽¹⁾ Includes shares owned by BioTime and ESI.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following weighted average common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands):

	Three Months Ended June 30, (unaudited)				Six Months Ended June 30, (unaudited)
	2019		2018		2019		2018
Stock options		15,374		8,990		15,103		8,990
Warrants (1)		-		8,795		-		8,795
BioTime Warrants (2) (Note 3)		1,296		-		917		-
Restricted stock units		271		535		275		535

(1)	The warrants expired on October 1, 2018.
(2)	Although the BioTime Warrants are classified as liabilities, these warrants are considered for dilutive earnings per share calculations in accordance with ASC 260, Earnings Per Share, and determined to be anti-dilutive for the period presented.

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands):

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
		(unaudited)				(unaudited)
Cash and cash equivalents	$	8,210	$	23,587	$	27,207	$	36,838
Restricted cash included in prepaid expenses and other current assets (see Note 15)		-		346		346		-
Restricted cash included in deposits and other long-term assets (see Note 15)		586		466		78		847
Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows	$	8,796	$	24,399	$	27,631	$	37,685